

# Hans Kaspar Binz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7516949/publications.pdf>

Version: 2024-02-01

19  
papers

2,525  
citations

567281

15  
h-index

996975

15  
g-index

21  
all docs

21  
docs citations

21  
times ranked

2495  
citing authors

#	ARTICLE	IF	CITATIONS
1	High-affinity binders selected from designed ankyrin repeat protein libraries. <i>Nature Biotechnology</i> , 2004, 22, 575-582.	17.5	598
2	Engineering novel binding proteins from nonimmunoglobulin domains. <i>Nature Biotechnology</i> , 2005, 23, 1257-1268.	17.5	598
3	Designing Repeat Proteins: Well-expressed, Soluble and Stable Proteins from Combinatorial Libraries of Consensus Ankyrin Repeat Proteins. <i>Journal of Molecular Biology</i> , 2003, 332, 489-503.	4.2	510
4	Engineered proteins as specific binding reagents. <i>Current Opinion in Biotechnology</i> , 2005, 16, 459-469.	6.6	142
5	Treatment of Diabetic Macular Edema With a Designed Ankyrin Repeat Protein That Binds Vascular Endothelial Growth Factor: A Phase I/II Study. <i>American Journal of Ophthalmology</i> , 2013, 155, 697-704.e2.	3.3	102
6	Consensus Design of Repeat Proteins. <i>ChemBioChem</i> , 2004, 5, 183-189.	2.6	96
7	Allosteric Inhibition of Aminoglycoside Phosphotransferase by a Designed Ankyrin Repeat Protein. <i>Structure</i> , 2005, 13, 1131-1141.	3.3	78
8	Treatment of Exudative Age-Related Macular Degeneration with a Designed Ankyrin Repeat Protein that Binds Vascular Endothelial Growth Factor: a Phase I/II Study. <i>American Journal of Ophthalmology</i> , 2014, 158, 724-732.e2.	3.3	70
9	Highly potent VEGF-A-antagonistic DARPins as anti-angiogenic agents for topical and intravitreal applications. <i>Angiogenesis</i> , 2013, 16, 101-111.	7.2	61
10	Design and characterization of MP0250, a tri-specific anti-HGF/anti-VEGF DARPIn® drug candidate. <i>MAbs</i> , 2017, 9, 1262-1269.	5.2	56
11	Half-life extension using serum albumin-binding DARPIn® domains. <i>Protein Engineering, Design and Selection</i> , 2017, 30, 583-591.	2.1	56
12	Beyond Antibodies: The DARPIn® Drug Platform. <i>BioDrugs</i> , 2020, 34, 423-433.	4.6	55
13	Characterization of a drug-targetable allosteric site regulating vascular endothelial growth factor signaling. <i>Angiogenesis</i> , 2018, 21, 533-543.	7.2	21
14	First-in-Human Phase I Study of MP0250, a First-in-Class DARPIn Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2021, 39, 145-154.	1.6	20
15	MP0250, a VEGF and HGF neutralizing DARPIn® molecule shows high anti-tumor efficacy in mouse xenograft and patient-derived tumor models. <i>Oncotarget</i> , 2017, 8, 98371-98383.	1.8	17
16	Abstract B25: First-in-human Phase I study to evaluate MP0250, a DARPIn blocking HGF and VEGF, in patients with advanced solid tumors. , 2015, , .		5
17	Abstract 3029: FAP-mediated tumor accumulation of a T-cell agonistic FAP/4-1BB DARPIn drug candidate analyzed by SPECT/CT and quantitative biodistribution. , 2018, , .		3
18	Abstract 3752: Preclinical pharmacology of MP0310: A 4-1BB/FAP bispecific DARPIn drug candidate promoting tumor-restricted T-cell costimulation. , 2018, , .		2

#	ARTICLE	IF	CITATIONS
19	Abstract 4552: Tumor-restricted immune modulation by multispecific molecules from the DARPIn toolbox. , 2018, , .		1